Lot WOL432 Save $25 Wolverine BPC-157 + TB-500

Research peptide · Lyophilized

Wolverine BPC-157 + TB-500

Wolverine BPC-157 + TB-500 — USA Made, ≥99% Purity

4.9 177 verified reviews

Balanced 10mg blend: BPC-157 5mg + TB-500 5mg
USA manufactured in GMP-certified California and Arizona laboratory facilities
≥99% component purity target with HPLC, mass spectrometry, and combined batch COA

Vial Size

Manufactured in a GMP facility · Independently tested · Batch COA

Dispatched from a US warehouse within 48 hours, tracked

Certificate of analysis for lot WOL432 below

Disclaimer

For research purposes only. Not intended for human consumption, medical use, diagnosis, treatment, or prevention of disease.

Specifications

Lot WOL432

Purity target

≥99%

≥99% per peptide component (3rd-Party HPLC Tested)

Components

BPC-157: 1,419.5 g/mol; TB-500: 889.01 g/mol

Vial content

10 MG

Lyophilized Powder

Sequences

BPC-157: GEPPPGKPADDAGLV; TB-500: Ac-LKKTETQ

CAS: BPC-157: 137525-51-0; TB-500: 885340-08-9
Molecular mass: BPC-157: 1,419.5 g/mol; TB-500: 889.01 g/mol
Purity target: ≥99% per peptide component (3rd-Party HPLC Tested)
Form: Lyophilized Powder
Origin: Manufactured, Formulated & Packaged in CA/AZ, USA
Storage: Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light

What is Wolverine BPC-157 + TB-500?

Wolverine is a two-component research blend containing 5mg of BPC-157 and 5mg of TB-500 for a total of 10mg per vial. BPC-157 is a 15-residue peptide, while TB-500 is the N-acetylated seven-residue fragment Ac-LKKTETQ from the actin-binding region of thymosin beta-4.

The compounds remain analytically distinct within the vial; blending them does not create a new peptide. Researchers can use the combination to examine two separate signaling profiles within one controlled experimental design.

How It Works

BPC-157 pathway: Preclinical studies examine VEGFR2, Akt/eNOS, FAK-paxillin, nitric-oxide, and cell-migration signaling.

TB-500 pathway: The Ac-LKKTETQ fragment represents a defined actin-binding motif studied in cytoskeletal and cell-motility models.

Parallel-pathway design: The blend lets researchers observe both compounds together without implying that they form a new molecule or a proven clinical synergy.

Analytical data

Every lot, on the record

Independent third-party HPLC evaluates the purity target, while mass spectrometry confirms molecular identity. Both results are documented in one combined, batch-specific Certificate of Analysis.

Purity (HPLC-UV)

99.53%

Net content

BPC-157 - 9.12 mg Thymosin Beta-4 - 10.56 mg

Reported

2026-06-12

Identity (LC-MS): Confirmed
Appearance: White Lyophilized Powder

HPLC MS

Analyte	Method	Result
Identity	LC-MS	Thymosin Beta-4/BPC-157
Purity	HPLC-UV	99.53%
Net Content		BPC-157 - 9.12 mg, Thymosin Beta-4 - 10.56 mg

Chromatogram

Mass confirmation

Download COA (PDF)

Why Source from 321 Peptides?

Two peptides, one accountable origin.

Both components are synthesized and finished in GMP-certified California and Arizona laboratory facilities, never sourced from overseas or Mexico.

Blend transparency.

Independent HPLC evaluates each component’s ≥99% purity target and mass spectrometry verifies identity. One batch-specific COA records the 5mg + 5mg composition and analytical results.

Freeze-dried together for stability.

Lyophilization protects the blended research material during storage and transit. Domestic fulfillment keeps handling fast and traceable.

Lot history 7 released lots

Every batch released under this compound, with the figure reported for each.

Lot	Reported	Purity	Net content	COA
WOL432	2026-06-12	99.53%	BPC-157 - 9.12 mg, Thymosin Beta-4 - 10.56 mg	PDF
WO-55604 Superseded	2026-05-12	99.52%	10.08 mg	Pending
WO-54450 Superseded	2026-05-06	99.88%	10.06 mg	Pending
WO-55027 Superseded	2026-05-02	99.71%	10.07 mg	Pending
WO-84241 Superseded	2026-04-23	99.46%	20.14 mg	Pending
WO-85395 Superseded	2026-04-08	99.83%	20.00 mg	Pending
WO-84818 Superseded	2026-03-19	99.58%	20.16 mg	Pending

Frequently Asked Questions

What is in the Wolverine 10mg peptide blend?

Each vial contains BPC-157 5mg and TB-500 5mg, for 10mg total research material. The two peptides remain separate compounds within the blend.

Which form of TB-500 is used in this specification?

This specification identifies TB-500 as the seven-residue N-acetylated fragment Ac-LKKTETQ, CAS 885340-08-9. It is not the full 43-amino-acid thymosin beta-4 molecule.